Hympavzi

Overview

Marketed; expanded indications approved June 2026

Generic name: marstacimab-hncq
Product class: Non-factor: anti-TFPI antibody (rebalancing)
Conditions: Hemophilia A or B with or without inhibitors
Route: Subcutaneous

Important safety information

Use official prescribing information and your care team for treatment decisions. This directory gives no dosing advice or medication prices.

Official product information Report a side effect to FDA

Side-effect reports go directly to the FDA, the manufacturer and your HTC. HemoLife Social never receives or stores them. In an emergency, call your local emergency number.

Member experiences

Reviews and community posts are visible only to signed-in members.

Related listings

Alhemo

Sources

Imported: 2026-10-26 · Individual verification pending

https://www.bleeding.org/healthcare-professionals/guidelines-on-care/products-licensed-in-the-us
https://bleedingdisordersnc.org/the-who-what-guide/
https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-hemophilia-or-b
https://www.pfizer.com/print/pdf/node/563413